VITA 34 AG Stock Deutsche Boerse AG

Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Delayed Deutsche Boerse AG 04:31:46 2024-06-03 EDT 5-day change 1st Jan Change
4.7 EUR +1.73% Intraday chart for VITA 34 AG +2.62% -8.56%

Financials

Sales 2024 * 79.1M 86.19M 118M Sales 2025 * 81.5M 88.81M 121M Capitalization 84.02M 91.56M 125M
Net income 2024 * -2M -2.18M -2.97M Net income 2025 * -1M -1.09M -1.49M EV / Sales 2024 * 1.15 x
Net Debt 2024 * 6.6M 7.19M 9.82M Net Debt 2025 * 1.4M 1.53M 2.08M EV / Sales 2025 * 1.05 x
P/E ratio 2024 *
-40.2 x
P/E ratio 2025 *
-53.6 x
Employees 745
Yield 2024 *
-
Yield 2025 *
-
Free-Float 30.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.73%
1 week+2.62%
Current month+1.73%
1 month+1.73%
3 months+1.95%
6 months+4.21%
Current year-8.56%
More quotes
1 week
4.52
Extreme 4.52
4.70
1 month
4.50
Extreme 4.5
4.70
Current year
3.91
Extreme 3.91
5.44
1 year
3.85
Extreme 3.85
6.24
3 years
3.85
Extreme 3.85
17.25
5 years
3.85
Extreme 3.85
17.70
10 years
3.50
Extreme 3.5
17.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 22-03-21
Director of Finance/CFO - 22-07-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 49 20-06-30
Chairman 59 21-12-14
Director/Board Member 51 -
More insiders
Date Price Change
24-06-03 4.7 +1.73%
24-05-31 4.62 +2.21%
24-05-30 4.52 -0.88%
24-05-29 4.56 0.00%
24-05-28 4.56 -0.44%

Delayed Quote Deutsche Boerse AG, June 03, 2024 at 04:31 am

More quotes
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.82 EUR
Average target price
5.3 EUR
Spread / Average Target
+9.96%
Consensus

Annual profits - Rate of surprise